Table 5.
QT-DDIs | Therapeutic class | TdP riska | Levels of QT-DDIsb | Frequency | |||
---|---|---|---|---|---|---|---|
Drug 1 | Drug 2 | Drug 1 | Drug 2 | Severity | Documentation | QT-DDIs: n (%)c | |
Ondansetron-Prochlorperazine | Antiemetic | Antipsychotic | Known risk of TdP | Not included in listsd | Major | Fair | 88 (30.6) |
Ciprofloxacin-Ondansetron | Antimicrobial | Antiemetic | Known risk of TdP | Known risk of TdP | Major | Fair | 71 (24.7) |
Ciprofloxacin-Prochlorperazine | Antimicrobial | Antipsychotic | Known risk of TdP | Not included in lists | Major | Fair | 64 (22.2) |
Ciprofloxacin-Metronidazole | Antimicrobial | Antimicrobial | Known risk of TdP | Conditional risk of TdP | Major | Fair | 10 (3.5) |
Ciprofloxacin-Dolasetron | Antimicrobial | Antiemetic | Known risk of TdP | Possible risk of TdP | Major | Fair | 6 (2.1) |
Dolasetron -Ondansetron | Antiemetic | Antiemetic | Possible risk of TdP | Known risk of TdP | Major | Fair | 5 (1.7) |
Dolasetron-Metronidazole | Antiemetic | Antimicrobial | Possible risk of TdP | Conditional risk of TdP | Major | Fair | 5 (1.7) |
Metronidazole-Ondansetron | Antimicrobial | Antiemetic | Conditional risk of TdP | Known risk of TdP | Major | Fair | 4 (1.4) |
Fluconazole-Metronidazole | Antimicrobial | Antimicrobial | Known risk of TdP | Conditional risk of TdP | Major | Fair | 3 (1) |
Prochlorperazine-Promethazine | Antipsychotic | Antiemetic | Not included in lists | Possible risk of TdP | Major | Fair | 2 (0.7) |
Ondansetron-Promethazine | Antiemetic | Antiemetic | Known risk of TdP | Conditional risk of TdP | Major | Fair | 2 (0.7) |
Metronidazole-Nilotinib | Antimicrobial | Kinase inhibitor | Conditional risk of TdP | Conditional risk of TdP | Major | Fair | 2 (0.7) |
Dolasetron-Octreotide | Antiemetic | Antidiarrheal | Possible risk of TdP | Not included in lists | Major | Fair | 2 (0.7) |
Clarithromycin-Ondansetron | Antimicrobial | Antiemetic | Known risk of TdP | Known risk of TdP | Major | Fair | 2 (0.7) |
Ciprofloxacin-Ketoconazole | Antimicrobial | Antimicrobial | Known risk of TdP | Conditional risk of TdP | Major | Fair | 2 (0.7) |
Ciprofloxacin-Fluconazole | Antimicrobial | Antimicrobial | Known risk of TdP | Known risk of TdP | Major | Fair | 2 (0.7) |
Prochlorperazine-Trimethoprim | Antipsychotic | Antimicrobial | Not included in lists | Not included in lists | Major | Fair | 1 (0.3) |
Prochlorperazine-Sulfamethoxazole | Antipsychotic | Antimicrobial | Not included in lists | Not included in lists | Major | Fair | 1 (0.3) |
Ondansetron-Tizanidine | Antiemetic | Muscle relaxant | Known risk of TdP | Not included in lists | Major | Fair | 1 (0.3) |
Nilotinib-Tizanidine | Kinase inhibitor | Muscle relaxant | Conditional risk of TdP | Not included in lists | Major | Fair | 1 (0.3) |
Metronidazole-Tizanidine | Antimicrobial | Muscle relaxant | Conditional risk of TdP | Not included in lists | Major | Fair | 1 (0.3) |
Metronidazole-Prochlorperazine | Antimicrobial | Antipsychotic | Conditional risk of TdP | Not included in lists | Major | Fair | 1 (0.3) |
Metronidazole-Norfloxacin | Antimicrobial | Antimicrobial | Conditional risk of TdP | Possible risk of TdP | Major | Fair | 1 (0.3) |
AZCERT Arizona Center for Education and Research on Therapeutics, TdP torsades de pointes, QT DDIs QT prolonging drug-drug interactions
aTdP risk was based on AZCERT QT drugs list
bLevels i.e., severity and documentation were based on Micromedex DrugReax® classification
cPercentage calculated in total number of QT-DDIs i.e., 288
dDrugs involved in QT-DDIs were not included in the AZCERT QT drugs lists